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Abstract
Polymorphic variants of the dopamine D4 receptor have been consistently associated with 
attention-deficit hyperactivity disorder (ADHD). However the functional significance of the risk 
polymorphism (variable number of tandem repeats in exon 3) is still unclear. Here we show that 
whereas the most frequent 4-repeat (D4.4) and the 2-repeat (D4.2) variants form functional 
heteromers with the short isoform of the dopamine D2 receptor (D2S), the 7-repeat risk allele 
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(D4.7) does not. D2 receptor activation in the D2S-D4 receptor heteromer potentiates D4 receptor-
mediated MAPK signaling in transfected cells and in the striatum, which did not occur in cells 
expressing D4.7 or in the striatum of knock-in mutant mice carrying the 7 repeats of the human 
D4.7 in the third intracellular loop of the D4 receptor. In the striatum D4 receptors are localized in 
cortico-striatal glutamatergic terminals, where they selectively modulate glutamatergic 
neurotransmission by interacting with D2S receptors. This interaction shows the same qualitative 
characteristics than the D2S-D4 receptor heteromer-mediated MAPK signaling and D2S receptor 
activation potentiates D4 receptor-mediated inibition of striatal glutamate release. It is therefore 
postulated that dysfunctional D2S-D4.7 heteromers may impair presynaptic dopaminergic control 
of corticostriatal glutamatergic neurotransmission and explain functional deficits associated with 
ADHD.
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Introduction
Dopamine D4 receptors are expressed in the prefrontal cortex (PFC), in GABAergic 
interneurons and in glutamatergic pyramidal neurons, including their striatal projections.1–3 
D4 receptors have been implicated in ADHD.1,4,5 In fact, the PFC and associated fronto-
striatal circuits are critical for executive function and are involved in ADHD.5 The gene 
encoding the human D4 receptor contains a large number of polymorphisms in its coding 
sequence.4 The most extensive polymorphism is found in exon 3, a region that codes for the 
third intracellular loop (3IL) of the receptor. This polymorphism consists of a variable 
number of tandem repeats (VNTR) in which a 48-bp sequence exists as 2- to 11-fold 
repeats.7 The three most common variants contain two, four and seven repeats (D4.2, D4.4 
and D4.7, respectively). D4.4 constitutes the most frequent variant, with a global frequency of 
64%, followed by D4.7 (21%) and D4.2 (8%).8 Importantly, a high prevalence of the D4.7 
variant has been demonstrated in children diagnosed with ADHD.5 Though stimulation of 
the D4,7 variant has been reported to be less potent at inhibiting cAMP than D4.2 or D4.4,9 
the functional significance of these variants are poorly understood.
Receptor heteromers are becoming the focus of extensive research in the field of G-protein-
coupled receptors.10 A receptor heteromer is currently defined as a macromolecular complex 
composed of at least two (functional) receptor units with biochemical properties that are 
demonstrably different from those of its individual components.10 In some cases, receptor 
heteromers provide a framework in which to understand the role of receptors with no clear 
functional significance, and example being the D3 receptor, which forms heteromers with 
the D1 receptor and modifies its function.11 A recent study showed that in mammalian 
transfected cells the long isoform of the D2 receptor (D2L) heteromerizes with the three main 
D4 receptor variants, D4.2, D4.4. and D4.7.12 Interestingly, results from the same study 
suggested that D4.7 was less effective in forming heteromers with D2L receptors.12 In view 
of the reported evidence of predominant co-localization of D4 receptors with the short 
isoform of the D2 receptor (D2S) in cortico-striatal glutamatergic terminals,2,3,13 we first 
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investigated if any of the three main human variants of the D4 receptor could interact both 
physically and functionally with D2S. By using the Bioluminescence Resonance Energy 
Transfer (BRET) technique, here we show evidence for the formation of heteromers 
between D2S and D4.2 and D4.4 variants of the D4 receptor. In contrast, the D4.7 variant 
failed to form heteromers with the D2S receptor. In transfected cells we found a biochemical 
property of the D2S-D4 receptor heteromer, which consists of the ability of D2S receptor 
activation to potentiate D4 receptor-mediated MAPK signaling. A similar result was 
observed in striata from wild-type mice, a species that expresses D4 receptors with a short 
3IL comparable to human D4.2. In contrast, potentiation of D4 receptor-mediated MAPK 
signaling was not observed in transfected cells expressing D4.7 or in striata taken from 
knock-in mice carrying a humanized 7 repeat intracellular loop identical to that found in 
human D4.7. Finally, analyzing neurotransmitter release in striatal slices and with in vivo 
microdialysis in rats, evidence was obtained for a key role of D2-D4 receptor interaction in 
the modulation of striatal glutamatergic neurotransmission.
Materials and methods
Fusion Proteins and Expression Vectors
The synthetic cDNAs for the human D4.2, D4.4 and, D4.7 receptor gene (kindly provided by 
T.P. Sakmar, Rockefeller University, USA) were amplified using sense oligonucleotide 
primer (5´- TCAACGGGACTTTCCAAAATGT-3´) and antisense primer (5´ 
CTCCGAGATCAACTTCTGCTCGCTTCGGTTACCC-3´) resulting in a cDNA fragment 
of 200 bp. A second product was generated using the sense oligonucleotide primer (5´- 
AAGTTGATCTCGGAGGAAGATACAGCAGATGCAG-3´) and antisense primer (5´- 
GCGAATTCGCAGCAAGCACGTAGAGCCTTACG-3´) resulting in a cDNA fragment of 
1500 bp. Equimolar quantities of both fragments were used to produce a third product 
corresponding to the myc-D4.2, myc-D4.4 or myc-D4.7 tagged gene using the sense primer (5
´- GTGCTCGAGCACCATGGGTAACCGAAGCACAG-3´) and antisense primer without 
its stop codon (5´- GCGAATTCTCAGCAGCAAGCACGTAGAGCCTTACG-3´) 
harbouring unique XhoI and EcoRI restriction sites, respectively. The fragments were then 
subcloned in-frame into XhoI/EcoRI sites of the pcDNA3.1 vector (Invitrogen). Next, the 
human cDNAs for the adenosine A1 receptor and dopamine D4.2, D4.4, D4.7 and D2S 
receptors, cloned in pcDNA3.1 were amplified without their stop codons using sense and 
antisense primers harboring unique XhoI and EcoRI sites to clone A1, D4.2, D4.4 and D4.7 
receptors in the RLuc and the YFP corresponding vectors, and HindIII and BamHI to clone 
D2S in the RLuc and the YFP corresponding vectors. The mouse cDNAs for the D4 and D2S 
receptors, cloned in pCMV-SPORT6 (ATCC, Manassas, USA) and pReceiver-M16 vectors 
respectively (GeneCopoeia, Rockville, USA), were amplified without their stop codons 
using sense and antisense primers harboring unique XhoI and EcoRV sites to clone D4 
receptor in the RLuc corresponding vector, and XhoI and KpnI to clone D2S receptor in the 
RLuc and the YFP corresponding vectors. The amplified fragments were subcloned to be in-
frame into restriction sites of the multiple cloning sites of EYFP-N3 vector (enhanced 
yellow variant of YFP; Clontech, Heidelberg, Germany) or the mammalian humanized 
pRluc-N1 vectors (Perkin-Elmer, Waltham, MA, USA) to give the plasmids that express the 
receptors fused to either Rluc or YFP on the C-terminal end of the receptor (D4.2-RLuc, 
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D4.4-RLuc, D4.7-Rluc, D2S-RLuc and A1-RLuc or D2S-YFP, D4.7-YFP, and D1-YFP, 
respectively). All constructs were verified by nucleotide sequencing and the fusion proteins 
are functional and expressed at the membrane level (see Results).
Cell Culture and transient transfection
Human embryonic kidney (HEK)-293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 
100 U/ml penicillin/streptomycin, and 5% (v/v) heat inactivated Foetal Bovine Serum (FBS) 
(all supplements were from Invitrogen, Paisley, Scotland, UK). CHO cell lines were 
maintained in α-MEM medium without nucleosides, containing 10% fetal calf serum, 50 
µg/ml penicillin, 50 µg/ml streptomycin and 2 mM L-glutamine (300 µg/mL). Cells were 
maintained at 37°C in an atmosphere of 5% CO2, and were passaged when they were 80–
90% confluent, twice a week. HEK-293T or CHO cells growing in 6-well dishes or in 25 
cm2 flasks were transiently transfected with the corresponding fusion protein cDNA by the 
PEI (PolyEthylenImine, Sigma, Steinheim, Germany) method as previously described.14
Immunostaining
For immunocytochemistry, HEK-293T cells were grown on glass coverslips and transiently 
transfected with 1 µg of cDNA corresponding to human D4.2-RLuc, D4.4-RLuc or D4.7-
RLuc and 0.5 µg of cDNA corresponding to human D2S-YFP or 0.8 µg of cDNA 
corresponding to mouse D4-RLuc and 0.5 µg of cDNA corresponding to mouse D2S-YFP. 
After 48h of transfection cells were fixed in 4% paraformaldehyde for 15 min and washed 
with phosphate-buffered saline contraining 20 mM glycine to quench the aldehyde groups. 
After permeabilization with phosphate-buffered saline containing 0.05% Triton X-100 for 
15 min, cells were treated with phosphate-buffered saline containing 1% bovine serum 
albumin. After 1 h at room temperature, cells were labeled with the primary rabbit 
monoclonal anti-human D4 receptor (1/10.000, Abcam, Cambridge, UK) or with the primary 
goat polyclonal anti-D4 receptor (1/500, Santa Cruz Biotechnology) for 1 h, washed and 
stained with the secondary antibody Cy3 anti-rabbit (1/200, Jackson ImmunoResearch, 
Baltimore, PA) or with the secondary antibody Cy3 anti-goat (1/200, Jackson 
ImmunoResearch, Baltimore, PA). The D2S-YFP construct was detected by its fluorescence 
properties. Samples were rinsed and observed in an Olympus confocal microscope.
BRET assay
HEK-293T cells were co-transfected with a constant amount of cDNA encoding for the 
receptor fused to Rluc and with increasingly amounts of cDNA encoding to the receptor 
fused to YFP to measure BRET as previously described (23). Both fluorescence and 
luminescence for each sample were measured before every experiment to confirm similar 
donor expressions (approximately 100,000 bioluminescence units) while monitoring the 
increase in acceptor expression (2000 to 20,000 fluorescence units). The relative amounts of 
BRET acceptor are expressed as the ratio between the net fluorescence of the acceptor and 
the luciferase activity of the donor being the net fluorescence the fluorescence of the 
acceptor minus the fluorescence detected in cells only expressing the donor. The BRET ratio 
is defined as [(emission at 510–590)/(emission at 440–500)] - Cf, where Cf corresponds to 
(emission at 510–590)/(emission at 440–500) for the D4-RLuc or D2S-Rluc constructs 
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expressed alone in the same experimental conditions. Curves were fitted by using a non-
linear regression equation, assuming a single phase with GraphPad Prism software (San 
Diego, CA, USA).
Generation of knockin mutant mice carrying human expansions in the 3IL of the D4 
receptor
A targeting vector was designed such that coding sequences of the 3IL of mouse Drd4 were 
replaced by human ortholog sequences corresponding to the most frequent 7-VNTR human 
variant allele (see Figure 4). The vector included a selectable PGK-neo cassette, flanked by 
two loxP sites, placed just downstream of Drd4 polyadenylation site and an HSV-thymidine 
kinase cassette placed at one of the extremes of the targeting vector to select for the absence 
of random integrations. A long and short arm of Drd4 homology were inserted flanking the 
swapped sequence and the selectable marker, respectively. The linearized vector was used to 
electroporate hybrid 129svev/C57BL/6 ES cells (inGenious Targeting Laboratory Inc., 
USA) and homologous recombinant clones were selected in the presence of G418 and 
gancyclovir. Two selected clones carrying the human 7-VNTR were used to microinject 
C57BL/6J blastocysts and one high percentage chimeric male mouse was used to produce 
heterozygote Drd4+/7repeat.neo mice. The neo cassette was excissed from the recombinant 
allele by crossing mutant mice with transgenic mice expressing Cre recombinase from an 
EIIa promoter (Jackson Laboratories, USA; Cat. No. 003724). The resulting heterozygote 
Drd4+/7repeat (D4.7 knockin) mice were successively bred to C57BL/6J mice to obtain a 
congenic heterozygote strain (n=10) that was used to establish a breeding colony. 
Homozygous D4.7 knockin mice and their wild-type littermates were used for the 
experiments. Knockin animals were characterized as indicated in Figure 4.
Mouse striatal slices preparation
Mice were housed five per cage in a temperature (21 ± 1°C) and humidity-controlled (55 ± 
10%) room with a 12:12 hours light/dark cycle (light between 08:00 and 20:00 hours) with 
food and water ad libitum. All animal procedures were conducted according to standard 
ethical guidelines (National Institutes of Health Animal care guidelines and European 
Communities Council Directive 86/609/EEC) and approved by the Local Ethical and 
Animal Care Committees. Transgenic mice and litter-mattes were decapitated with a 
guillotine and the brains were rapidly removed and placed in ice-cold oxygenated (O2/
CO2:95%/5%) Krebs-HCO3− buffer (124 mM NaCl, 4 mM KCl, 1.25 mM NaH2PO4, 1.5 
mM MgCl2, 1.5 mM CaCl2, 10 mM glucose and 26 mM NaHCO3, pH 7.4). The brains were 
sliced at 4°C in a brain matrix (Zivic Instruments, Pittsburgh, PA, USA) into 0.5 mm 
coronal slices. Slices were kept at 4°C in Krebs-HCO3− buffer during the dissection of the 
striatum. Each slice was transferred into an incubation tube containing 1 ml of ice-cold 
Krebs-HCO3− buffer. The temperature was raised to 23°C and after 30 min, the media was 
replaced by 2 ml Krebs-HCO3− buffer (23°C).
ERK phosphorylation assay
Striatal slices from transgenic mice and litter-mattes were incubated under constant 
oxygenation (O2/CO2:95%/5%) at 30°C for 4–5 h in an Eppendorf Thermomixer (5 Prime, 
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Inc., Boulder, CO, USA) with Krebs-HCO3− buffer. The media was replaced by 200 µl of 
fresh Krebs-HCO3− buffer and incubated for 30 min before the addition of ligands. 
Transfected CHO cells were cultured in serum-free medium for 16 h before the addition of 
the indicated concentration of ligands for the indicated time. Both, cells and slices were 
lysed in ice-cold lysis buffer (50 mM Tris- HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM 
β-glycerophosphate, 1% Triton X-100, 20 µM phenylarsine oxide, 0.4 mM NaVO4 and 
protease inhibitor cocktail). Cellular debris was removed by centrifugation at 13,000 g for 5 
min at 4°C and protein was quantified by the bicinchoninic acid method using bovine serum 
albumin dilutions as standard. To determine the level of ERK1/2 phosphorylation, 
equivalent amounts of protein (10 µg) were separated by electrophoresis on a denaturing 
10% SDS-polyacrylamide gel and transferred onto PVDF-FL membranes. Odyssey blocking 
buffer (LICOR Biosciences, Lincoln, Nebraska, USA) was then added and membranes were 
blocked for 90 min. Membranes were then probed with a mixture of a mouse anti-phospho-
ERK 1/2 antibody (1:2500, Sigma, Steinheim, Germany) and rabbit anti-ERK 1/2 antibody 
(1:40000, Sigma) for 2–3 h. Bands were visualized by the addition of a mixture of IRDye 
800 (anti-mouse) antibody (1:10000, Sigma) and IRDye 680 (anti-rabbit) antibody (1:10000, 
Sigma) for 1 h and scanned by the Odyssey infrared scanner (LICOR Biosciences, Lincoln, 
Nebraska, USA). Bands densities were quantified using the scanner software and exported 
to Excel (Microsoft, Redmond, WA, USA). The level of phosphorylated ERK1/2 isoforms 
was normalized for differences in loading using the total ERK protein band intensities.
In vivo microdialysis in rat striatum
Male Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA, USA), weighing 
300–350 g were used. Concentric microdialysis probes with 2-mm long dialysis membranes 
were prepared as described previously.15 Animals were anesthetized with Equithesin (NIDA 
Pharmacy, Baltimore, MD, USA) and microdialysis probes were implanted in the ventral 
striatum (core of the nucleus accumbens); coordinates with respect to bregma: A 1.7, L +1.2 
and V -7.6 mm. The experiments were performed on freely moving rats 24 h after the probe 
implantation. A Ringer solution (in mmol/l) of 147 NaCl, 4 KCl, and 2.2 CaCl2 was pumped 
through the dialysis probe at a constant rate of 1 µl/min. After a washout period of 90 min, 
samples were collected at 20-min intervals and split into two fractions of 10 µL, to 
separately measure glutamate and dopamine contents. Each animal was used to study the 
effect of one treatment by local administration (perfusion by reverse dialysis) of the D4 
receptor agonist RO-10-5824 or the D4 receptor antagonist L-745,870. At the end of the 
experiment, rats were killed with an overdose of Equithesin and methylene blue was 
perfused through the probe. The brain was removed and placed in a 10% formaldehyde 
solution, and coronal sections were cut to verify the probe location. Dopamine content was 
measured by reverse high-performance liquid chromatography (HPLC) coupled to an 
electrochemical detector, as described in detail previously.15 Glutamate content was 
measured by HPLC coupled to a flourimetric detector, as described before.16 The limit of 
detection (which represents three times baseline noise levels) for dopamine and glutamate 
was 0.5 and 50 nM, respectively. Dopamine and glutamate values were transformed as 
percentage of the mean of the three values before the stimulation and transformed values 
were statistically analyzed with one-way repeated measures ANOVA followed by Newman-
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Keuls tests, to compare glutamate and dopamine values of the samples obtained after drug 
perfusion with those obtained just before drug perfusion.
Neurotransmitter release in rat striatal slices
Rat brain slices were obtained from male Wistar rats weighing 180–220 g. After rapid 
sacrifice of the rat, the brain was immersed in oxygenated ice-cold artificial cerebrospinal 
fluid (ACSF) solution, and coronal brain slices (300 µm thick) were obtained with a 
vibratome. The striatum (caudate-putamen and nucleus accumbens) was microdissected 
under a stereoscopic microscope and the slices were incubated for 30 min at 37°C in ACSF 
(in mM: NaCl 118.25, KCl 1.75, MgSO4 1, KH2PO4 1.25, NaHCO3 25, CaCl2 2, and D-
glucose 10.), gassed continuously with O2/CO2 (95:5, v/v). For GABA release, the slices 
were then incubated for 30 min with 8 nM [3H]GABA in 2 ml solution containing 10 µM 
aminooxyacetic acid (to inhibit GABA transaminase, thus preventing degradation of the 
labeled GABA). At the end of this period, excess radiolabeled compound was removed by 
washing twice with ACSF containing, in addition to aminooxyacetic acid and 10 µM 
nipecotic acid (to prevent the reuptake of the released [3H]GABA). Both compounds were 
present in the perfusion solution for the rest of the experiment. For dopamine release, the 
slices were labeled with 77 nM [3H]dopamine in Krebs–Henseleit solution containing 10 
µM pargyline, 0.57 mM ascorbic acid and 0.03 mM EDTA, which were present in the 
solutions for the rest of the experiment. For glutamate release, the tissues were incubated for 
30 min with 100 nM [3H]glutamate in 2 ml of artificial CSF containing 200 µM 
aminooxyacetic acid (to inhibit glutamate decarboxylase and prevent the conversion of 
glutamate to GABA) and 200 µM dihydrokainic acid (to prevent the uptake of 
[3H]glutamate by astrocytes). Dihydrokainic acid was present in the medium only during the 
incubation period. At the end of this period, the excess radiolabeled compound was removed 
by washing twice with artificial CSF. Methods for measuring [3H]neurotransmitter release 
and data analysis used in the present work were the same as those described previously.17,18 
The slices were apportioned randomly between the chambers (usually three slices per 
chamber) of a superfusion system (volume of each chamber 80 µl; 20 chambers in parallel) 
and perfused with the artificial CSF at a flow rate of 0.5 ml/min for 1 h. Basal release of 
[3H]neurotransmitter was measured by collecting 4 fractions of the superfusate (total volume 
2 ml) before depolarizing the slices with a solution in which the [K+] was raised to 25 mM. 
The composition of the high K+ solution was (in mM): NaCl 101.25, KCl 23.75, MgSO4 1, 
KH2PO4 1.25, NaHCO3 25, CaCl2 2 and D-glucose 10. Six more fractions were collected in 
the high K+ medium. All drugs were added to the medium at fraction 2, before changing the 
superfusion to the high K+ medium, to explore effects on basal release. To determine the 
total amount of tritium remaining in the tissue, the slices were collected, treated with 1 ml of 
1 M HCl and allowed to stand for 1 h before adding the scintillator. The 
[3H]neurotransmitter release was expressed initially as a fraction of the total amount of 
tritium remaining in the tissue. The effect of drugs on the basal release of 
[3H]neurotransmitter was assessed by comparing the fractional release in fraction 2 
(immediately before exposure of the tissue to the drug) and fraction four (immediately prior 
to exposure to 25 mM of K+), using Student’s paired t test. Changes in depolarization-
induced [3H]GABA release by drugs and treatments, were assessed by comparing the area 
under the appropriate release curves between the first and last fractions collected after the 
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change to high K+. The significance of drug effects was assessed by one-way ANOVA and 
Tukey-Kramer test, using Prism Graph Pad Software 4.0, (Graph Pad Software, San Diego 
CA, USA). To obtain an unbiased estimate of IC50 values, concentration-response data were 
fitted by non-linear regression using the same software.
Statistical Analysis
Statistical analyses were performed with Prism Graph Pad Software 4.0, (Graph Pad 
Software, San Diego CA, USA). See above and figure legends for details.
Results
D2S and D4 receptors form heteromers in transfected cells
BRET experiments were performed where one of the receptor is fused to the bioluminescent 
protein Renilla Luciferase (RLuc) and the other receptor is fused to a yellow fluorescent 
protein (YFP). The fusion proteins were functional (Supplementary Figure 1) and expressed 
at the membrane level (Figure 1c). Clear BRET saturation curves were obtained in cells 
expressing D4.2-RLuc or D4.4-RLuc receptors and increasing amounts of D2S-YFP (Figure 
1a), but not in cells expressing D4.2-RLuc or D4.4-RLuc receptors and increasing amounts of 
D1-YFP (Figure 1a), indicating that the D4.2 and the D4.4 form heteromers with D2S but not 
with D1 receptors. Interestingly, in cells expressing the D4.7-Rluc variant and D1-YFP or 
D2S-YFP (Figure 1a) low linear BRET was detected, which was qualitatively similar to the 
results obtained with the negative control, with adenosine A1-RLuc and D2S-YFP receptors 
(Figure 1a). This result was not due to the particular BRET donor and acceptor chosen, as 
low and linear BRET were obtained when we swapped the fused proteins, i.e., in cells co-
expressing D2S-Rluc and D4.7-YFP (Figure 1a). These results strongly suggest that the 
human D4.7 polymorphic variant does not form heteromers with the human D2S receptor or 
if heteromers are formed, the fusion proteins are not properly oriented or are not within 
proximity to allow energy transfer (less than 10 nm). One way to test if the receptors are 
indeed forming heteromers in such a way that impedes energy transfer is to titrate one 
receptor in the presence of the heteromer and look for changes in the BRET signal. In BRET 
displacement experiments, D4.2, but not D4.7 receptors were able to compete with D4.4-Rluc 
and alter heteromer formation with D2S-YFP (Figure 1b), meaning that D4.2 and D4.4, but 
not D4.7 receptors use the same molecular determinants to establish intermolecular 
interactions with D2S receptor and strongly suggesting that D4.7 receptors are unable to form 
heteromers with D2S.
D2S-D4 receptor heteromer signals through MAPK
To investigate the function of the D2S-D4 receptor heteromer, MAPK signaling (ERK1/2 
phosphorylation) was determined. RO-10-5824 and quinelorane, selective D4 and D2/3 
receptor agonists respectively,19,20 selectively stimulated MAPK in cells transfected with D4 
or D2S receptors, respectively (Supplementary Figure 2). Dose-response experiments with 
RO-10-5824 showed no significant differences between cells transfected with D4.2, D4.4 or 
D4.7 receptors (Supplementary Figure 2). However, in co-transfected cells, stimulation of 
D2S receptors potentiated D4 receptor-mediated MAPK activation, but not the other way 
around. Importantly, this functional interaction only occurred in cells transfected with D2S 
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and D4.2 or D4.4, but not in cells expressing D4.7 receptors (Figure 2). Since disruption of 
D2S-D4 receptor heteromers (by substituting D4.2 or D4.4 with the D4.7 variant) is associated 
with the loss of the D2S-D4 receptor interaction at the MAPK level, this interaction 
constitutes a specific biochemical property of the D2S-D4 receptor heteromer and can be 
used as a biochemical fingerprint to detect the heteromer in native tissues.10
D2S-D4 receptor heteromers in the mouse brain
D4 receptors are preferentially expressed in limbic areas and the PFC, where they can be 
found in interneurons and also projecting neurons.1 In cortico-striatal neurons D4 receptors 
have also been localized at their nerve terminals,2,3 where they can co-localize with D2S 
receptors.13 We therefore investigated the existence of D2S-D4 receptor heteromers in the 
striatum. Biophysical techniques cannot be easily applied in native tissues, but indirect 
methods can be used, such as the identification of a biochemical property of the heteromer 
(biochemical fingerprint).10 In this case, the biochemical fingerprint would be the 
potentiation by D2S receptor activation of D4 receptor-mediated MAPK activation, which 
should not occur with the human D4.7 variant. Prior to these experiments with mouse brain, 
we demonstrated by BRET saturation experiments in transfected cells that the mouse D2S 
receptor forms heteromers with the mouse D4 receptor (which has an amino acid sequence 
in the 3IL similar to that from the human D4.2). Mouse fusion proteins were expressed in the 
plasma membrane of transfected cells (Figure 3a) and shown to be functional 
(Supplementary Figure 3). Like the human receptors, mouse D2S receptors were found to 
form heteromers with mouse D4 receptors and also with human D4.4 receptors, but not with 
human D4.7 receptors (Figure 3b). Furthermore, it was also shown that, in co-transfected 
cells, stimulation of the mouse D2S receptor potentiates the effect of the mouse D4, but not 
the human D4.7, on MAPK signaling (Figures 3c,d). This result was not reciprocal 
(Supplementary Figure 4) and mirrors the results obtained with human D4 and D2S receptors 
(Figure 2). We next analyzed the effects of D2 and D4 receptor agonists on MAPK signaling 
on striatal slices taken from knock-in mice carrying the 7 repeats of the human D4.7 in 
replacement of the mouse region and from wild-type littermates (Figure 4). Neither 
quinelorane nor RO-10-5824 induced a significant ERK1/2 phosphorylation in striatal slices 
of wild-type mice when administered alone, but co-administration of both agonists produced 
a significant dose-dependent effect with an increase of up to four fold (Figure 3e). This 
synergistic interaction between D2 and D4 receptors, which constitutes the biochemical 
fingerprint of the D2S-D4 receptor heteromer, was completely absent in the D4.7 mutant 
mouse (Figure 3e), confirming both the existence of D2S-D4 receptor heteromers and the 
absence of functional interactions between D2 and D4.7 receptors in the brain.
D2-D4 receptor interactions modulate striatal glutamate release
To investigate the functional significance of D4 receptor activation we determined D4 
receptor-mediated modulation of striatal glutamate release by in vivo microdialysis in freely 
moving rats. The local perfusion of the D4 receptor agonist RO-10-5824 in the ventral 
striatum (in the nucleus accumbens) produced a dose-dependent decrease in the striatal 
extracellular concentration of glutamate and a concomitant increase in the extracellular 
concentration of dopamine (Figure 5a and 5b), which were counteracted by co-perfusion 
with the selective D4 receptor antagonist L-745,870 (which was inactive when perfused 
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alone) (Figure 5a, 5b and 5c). These results suggest that inhibitory D4 receptors are located 
in glutamatergic terminals, whose activation decreases basal striatal glutamate release. The 
increase in dopamine concentration can best be explained by a decreased activation of 
striatal GABAergic efferent neurons that tonically inhibit dopaminergic mesencephalic 
neurons. This interpretation could be confirmed in experiments with striatal slices, where 
dopamine should not be modified due to the interruption of the striatal-mesencephalic loop. 
In fact, in slices of dorsal or ventral rat striatum, the D4 receptor agonist RO-10-5824 
decreased K+-induced glutamate release, an effect that was counteracted by the selective D4 
receptor antagonist L-745,870, but did not change dopamine or GABA release (Figure 6), 
indicating that striatal D4 receptors selectively and locally modulate glutamate release. This 
role of D4 receptors in the striatum can also explain previous results obtained with D4 
receptor KO mice, which show an increase and decrease in the striatal extracellular 
concentration of glutamate and dopamine, respectively.21,22
As mentioned before, there is evidence for co-localization of both D2 and D4 receptors in 
cortico-striatal glutamatergic terminals2,3,13 and previous studies have demonstrated that 
presynaptic D2-like receptors play an inhibitory role in the modulation of striatal glutamate 
release.13,23 However, since those studies did not use selective compounds, they could not 
distinguish between effects due to D2 or D4 receptor stimulation. Therefore, in this study we 
tested the effect of quinelorane alone and in combination with RO-10-5824 on glutamate 
release in rat striatal slices. To eliminate endogenous dopamine, rats were treated with 
reserpine, and the experiments performed in the presence of the D1-like receptor antagonist 
SCH-23390. Quinelorane significantly decreased K+-induced glutamate release whereas the 
co-application of quinelorane with RO-10-5824 showed a more significant effect (Figure 
7a). Dopamine strongly decreased K+-induced glutamate release, an effect partially 
counteracted by the D2 receptor antagonist L-741,626 or by the D4 receptor antagonist 
L-745,870, but completely counteracted by the simultaneous application of both antagonists 
(Figure 7b). In agreement with the reported higher in vitro affinity of D4 versus D2 receptor 
for dopamine,24 the IC50 of dopamine-mediated inhibition of K+-induced glutamate release 
was significantly higher in the presence of the D4 receptor antagonist (D2-mediated effect) 
than in the presence of the D2 receptor antagonist (D4-mediated effect) (Figure 7b). Finally, 
and more importantly, the D2 receptor agonist quinelorane synergistically potentiated the 
inhibitory effect of the D4 receptor agonist RO-10-5824 on K+-induced glutamate release 
(significant decrease in IC50 value) (Figure 7c), but not the other way around (Figure 7d). 
These results therefore show the same kind of D2-D4 receptor interaction demonstrated by 
D2S-D4 receptor heteromers in transfected cells with MAPK signaling. Our combined in 
vitro and in vivo data strongly suggest that D2S-D4 receptor heteromers are likely to play a 
key role in dopamine-mediated modulation of striatal glutamate release
Discussion
The present study shows that dopamine D2S and D4.2 or D4.4 receptors, but not the ADHD-
associated human D4.7 variant, form functional heteromers in transfected cells and in the 
rodent brain. Co-stimulation of D2S and D4 receptors in the D2S-D4 receptor heteromer has a 
synergistic effect on MAPK signaling, which could be demonstrated in transfected cells and 
in the mouse striatum, but not in cells expressing D4.7 or in the striatum of a mutant mouse 
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carrying the 7 repeats of the human D4.7 in the 3IL of the D4 receptor. These results provide 
a significant functional difference of one of the human receptor variants, D4.7, compared to 
the D4.2 and D4.4 variants, which can have important implications for the understanding of 
the pathogenesis of ADHD. Importantly, we also demonstrated, for the first time, that D2S-
D4 receptor interactions modulate striatal glutamate release suggesting that the D2S-D4 
receptor heteromer allows dopamine to fine-tune glutamate neurotransmission.
The molecular mechanism involved in preventing heteromer formation between D2S and 
D4.7 receptors is not yet known. Indeed, the control of heteromer formation between GPCRs 
is still a large question in the field. Since the D4.7 receptor variant has the longest 3IL and is 
the only polymorphic form not forming heteromers with the D2S receptor, steric hindrance 
of the 3IL of D4.7 receptor is a probable mechanism responsible for this lack of 
heteromerization, but other mechanisms cannot be ruled out. Using two-hybrid 
methodologies as well as proteomic studies, interactions between dopamine receptors and a 
cohort of dopamine receptor interacting proteins (DRIPs) have been demonstrated, forming 
signaling complexes or signalplexes.25,26 Some of these DRIPs show selectivity for some 
dopamine receptor subtypes. For example, filamin or protein 4.1N interact with D2 and D3 
receptors but not with D1, D5 or D4 receptors,27,28 the PDZ domain-containing protein, 
GIPC (GAIP interacting protein, C terminus) interacts with D2 and D3 receptor but not with 
the D4 receptor subtype29 and paralemmin interacts exclusively with D3, but not with D2 or 
D4 receptors.30 All of these interactions modulate receptor targeting, trafficking and 
signaling. Proline-rich sequences of the D4 receptor, mainly located in the polymorphic 
region of the 3IL, constitute putative SH3 binding domains which can potentially interact 
with adapter proteins like Grb2 and Nck, which do not have any known catalytic activity but 
are capable of recruiting multiprotein complexes to the receptor.24 It can be hypothetized 
that differences in DRIPs recruitment by D4.7 and the other D4 polymorphic forms can 
influence the D4.7 ability to form heteromers, but future studies will be required.
Previous experiments indicated that locally in the striatum dopamine inhibits glutamate 
release by activating D2 receptors (predominantly D2S) localized in glutamatergic 
terminals.13,23 Other studies also indicate that striatal postsynaptic D2 receptors 
(predominantly D2L) indirectly modulate glutamate release by retrograde endocannabinoids 
signaling.31 The present results indicate that D4 receptors also play a key role in the 
modulation of striatal glutamate release, likely through its ability to form heteromers with 
presynaptic D2S receptors. In the striatal D2S-D4 receptor heteromer, low concentrations of 
dopamine should bind to the D4 receptor, which has more affinity for dopamine than the D2S 
receptor,24 causing a certain degree of inhibition of glutamate release. However, at higher 
concentrations, dopamine should also bind to the D2S receptor and under these conditions 
the synergistic interaction in the D2S-D4 receptor heteromer will produce an even stronger 
inhibition of glutamate release. Therefore, the D2S-D4 receptor heteromer seems to act as a 
concentration-dependent device that establishes two different degrees of presynaptic 
dopaminergic control over striatal glutamatergic neurotransmission. Since the strong 
modulation observed with higher concentrations of dopamine depends on D2S-D4 receptor 
heteromerization, the existence of a D4.7 variant implies a weaker control of glutamatergic 
neurotransmission, which could be a main mechanism involved in the pathogenesis of 
ADHD. This could also explain at least part of the so far not understood successful effect of 
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psychostimulants in ADHD, which amplify dopaminergic signaling and these medications 
appear to be more effective in ADHD patients with the D4.4 than with the D4.7 variants.32,33 
We have to take into account that the existence of a D4.7 variant does not imply ADHD is 
the result of this variant, but rather that it is one factor that contributes to its development. In 
fact, the D4.7 variant might constitute a successful evolutionary trait under the appropriate 
environmental exposure.7,34 The present study provides a new element of interest in the 
field of receptor heteromes, which now become new targets to be studied when dealing with 
functional differences associated with polymorphisms of G-protein-coupled receptor genes.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Human D2S and D4 receptors form heteromers in transfected cells
a) BRET saturation curves were obtained from experiments with cells co-expressing, top to 
bottom, D2S-YFP and D4.2-RLuc (red), D4.4-RLuc (green) or D4.7-Rluc (blue), D2S-RLuc 
and D4.7-YFP (purple), A1-RLuc and D2S-YFP (black) or D4.4-RLuc and D1-YFP (gray). 
Co-transfections were performed with a constant amount of cDNA corresponding to the 
receptor-RLuc construct (2 µg of cDNA for D4-RLuc or 1 µg of cDNA for A1-RLuc) and 
increasing amounts of cDNA corresponding to the receptor-YFP construct (0.2–6 µg of 
cDNA for D2S-YFP or 1–4 µg of cDNA for D1-YFP). Both fluorescence and luminescence 
of each sample were measured prior to every experiment to confirm equal expression of 
Rluc (about 100,000 luminescence units) while monitoring the increase of YFP expression 
(2000 to 20,000 fluorescence units). BRET data are expressed as means ± S.D. of four to 
nine different experiments grouped as a function of the amount of BRET acceptor. (b) 
BRET displacement experiments were performed in cells expressing constant amounts of 
D4.4-RLuc (2 µg cDNA transfected) and D2S-YFP (2µg cDNA tranfected) and increasing 
amounts (1–5 µg of cDNA transfected) of D4.7 (blue) or D4.2 (green). Both fluorescence and 
luminescence of each sample were measured prior to every experiment to confirm no 
changes in the expression of D4.4-RLuc and D2S-YFP. BRET data are expressed as means ± 
S.D. of five different experiments grouped as a function of the amount of BRET acceptor. 
Significant differences with respect to the samples without D4.2 or D4.7 were calculated by 
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one-way ANOVA and Bonferroni’s test. (**P < 0.01 and ***P < 0.001). In (a) and (b) the 
relative amounts of BRET acceptor are expressed as the ratio between the fluorescence of 
the acceptor minus the fluorescence detected in cells only expressing the donor, and the 
luciferase activity of the donor. In the top, schematic representations of BRET (a) or BRET 
displacement (b) are shown. (c) Confocal microscopy images of cells transfected with 1 µg 
of cDNA corresponding to, left to right, D4.2-RLuc, D4.4-RLuc or D4.7-RLuc and 0.5 µg 
cDNA corresponding to D2S-YFP. Proteins were identified by fluorescence or by 
immunocytochemistry. D4-RLuc receptors are shown in red, D2S-YFP is shown in green and 
co-localization is shown in yellow. Scale bar: 5 µm.
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Figure 2. Crosstalk between human D4 and D2S receptors in ERK 1/2 phosphorylation
Cells were transiently co-transfected with 2.5 µg of cDNA corresponding to D2S and 2.5 µg 
of cDNA corresponding to D4.2 (a and d), D4.4 (b and e) or D4.7 (c and f). In a, b and c, 
cells were treated for 10 min with increasing concentrations of RO 10-5824 in the presence 
(○) or in the absence (●) of quinelorane (50 nM). In d, e and f, cells were treated for 10 min 
with increasing concentrations of quinelorane in the presence (○) or in the absence (●) of 
RO 10-5824 (50 nM). The immunoreactive bands, corresponding to ERK 1/2 
phosphorylation, of three to six experiments were quantified and expressed as arbitrary 
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units. For each curve EC50 values were calculated as mean ± S.E.M. and statistical 
differences between curves obtained in the presence or in the absence of quinelorane (a, b 
and c) or RO 10-5824 (d, e and f) were determined by Student’s t test. EC50 with and 
without quinelorane: (a) 9 ± 1 and 26 ± 1nM (p<0.01), (b) 7 ± 1 and 23 ± 1nM (p<0.01), (c) 
18 ± 1 and 22 ± 1 nM (N.S.). EC50 with and without RO 10-5824: (d) 22 ± 1 and 20 ± 1 nM 
(N.S.), (e) 20 ± 1 and 17 ± 1 nM (N.S.), (f) 18 ± 1 and 13 ± 1nM (N.S.). N.S.: non-statistical 
differences
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Figure 3. D2s-D4 receptor heteromers in the mouse brain
(a) Confocal microscopy images of cells transfected with 1 µg of cDNA corresponding to, 
left to right, mouse D4-RLuc, human D4.4-RLuc and human D4.7-RLuc and 0.5 µg of cDNA 
corresponding to D2S-YFP. Proteins were identified by fluorescence or by 
immunocytochemistry. D4-RLuc receptors are shown in red, D2S-YFP is shown in green and 
co-localization is shown in yellow. Scale bar: 5 µm. (b) Mouse D2S receptor 
heteromerization with mouse and human D4 receptors. BRET saturation curves were 
obtained from cells co-expressing mouse D4-Rluc (green), human D4.4-RLuc (red), human 
D4.7-RLuc (blue) or human A1-RLuc (gray) and mouse D2S-YFP receptors. Co-transfections 
were performed with a constant amount of cDNA corresponding to the receptor-RLuc 
construct (2 µg of cDNA for mouse D4-RLuc, 2.5 µg of cDNA for human D4-RLuc or 1 µg 
of cDNA for A1-RLuc) and increasing amounts of cDNA corresponding to the receptor-YFP 
construct (0.2–6 µg cDNA). Both fluorescence and luminescence of each sample were 
measured prior to every experiment to confirm equal expression of Rluc (about 100,000 
luminescence units) while monitoring the increase of YFP expression (2000 to 20,000 
fluorescence units). The relative amounts of BRET acceptor are expressed as the ratio 
between the fluorescence of the acceptor minus the fluorescence detected in cells only 
expressing the donor, and the luciferase activity of the donor. BRET data are expressed as 
means ± S.D. of three to six different experiments grouped as a function of the amount of 
BRET acceptor. (c) and (d) Crosstalk between mouse D2S receptors and mouse or human D4 
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receptors in ERK 1/2 phosphorylation. Cells transiently co-expressing mouse D2S receptors 
and mouse D4 receptors (c) or human D4.7 receptors (d) were treated for 10 minutes with 
increasing RO 10-5824 concentrations in the presence (○) or in the absence (●) of 
quinelorane (50 nM) prior to the ERK 1/2 phosphorylation determination. The 
immunoreactive bands of three experiments (mean ± SEM; n = 3) were quantified and 
expressed as arbitrary units. EC50 values with or without quinelorane were: (c) 7 ± 0.1 and 
15 ± 0.1 nM (Student’s t test: p<0.01) or (d) 18 ± 0.1 and 15 ± 0.1 nM (Student’s t test: NS). 
(e) Striatal slices from wild-type (WT) or D4.7 mutant mice were treated for 10 min with the 
indicated concentrations of RO 10-5824 (orange) or quinelorane (green) or with RO 
10-5824 plus quinelorane (blue) and ERK 1/2 phosphorylation was determined. For each 
treatment, the immunoreactive bands from 4 to 6 slices from a total 10 WT and 10 D4.7 
mutant animals were quantified and values represent the mean ± S.E.M. of the percentage of 
phosphorylation relative to basal levels found in untreated slices (100 %). No significant 
differences were obtained between the basal levels of the WT and the D4.7 mutant mice. 
Significant treatment and genotype effects were shown by a bifactorial ANOVA followed 
by post-hoc Bonferroni’s tests (** and ***: p<0.01 and p<0.001, respectively, as compared 
to the lowest concentration of RO 10-5824)
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Figure 4. Targeted insertion of human VNTRs carrying 7 repeats into the mouse Drd4 exon 3 by 
homologous recombination in ES cells
(a) Structure of the Drd4 locus, targeting vector and targeted allele. (b) Southern blot 
analysis detected double homologous recombination events at the 5' and 3' ends using 
external probes after digestion with BamHI or EcoRI. (c) The presence of inserted human 
VNTR was verified by PCR using mouse primers flanking the expansion.
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Figure 5. In vivo D4 receptor-mediated modulation of basal extracellular levels of glutamate in 
the rat ventral striatum
Effects of the local perfusion with the D4 receptor agonist RO 10-5824 and the D4 receptor 
antagonist L-745,870 on the basal extracellular concentrations of glutamate (GLU) and 
dopamine (DA) in the ventral striatum (core of the nucleus accumbens). Horizontal bars 
show the periods of drug perfusion (concentrations are indicated in M). Data represent 
means ± S.E.M. of the percentage of the mean of the three basal values before the first drug 
perfusion (n = 6–8/group): * and **: p<0.05 and 0.01, respectively, compared to the values 
previous in time “0” (repeated measures ANOVA followed by Newman-Keuls tests).
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Figure 6. D4 receptor-mediated modulation of [
3H]glutamate, but not [3H]dopamine or 
[3H]GABA release from slices of dorsal and ventral striatum
Slices from the dorsal striatum (caudate-putamen; a, c and e) or the ventral striatum (nucleus 
accumbens; b, d and f) of reserpine-treated rats were treated with the D4 receptor agonist 
RO 10-5824 (100 nM) or with the D4 receptor antagonist L745,870 (10 nM) alone or in 
combination and the time course of K+ stimulated [3H]glutamate (a and b), [3H]dopamine (c 
and d) or [3H]GABA (e and f) release was determined. The RO 10-5824-induced effect 
(open circles) was prevented by the antagonist L 745,870 (dark squares) which itself had no 
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effect (open squares). Values are mean ± S.E.M. of samples from 3 different animals 
performed in 4 replicates. Drug effect was assessed by comparing the relative area under the 
curve for each condition. **: p<0.01 with respect to the control (ANOVA followed by 
Tukey-Kramer multiple comparison post hoc test).
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Figure 7. D2 and D4 receptor interactions in the modulation of striatal [
3H]glutamate release
Striatal slices (dorsal striatum) from reserpine-treated rats were incubated with SCH 23390 
(100 nM) to block D1 receptor activation. In (a), slices were treated for 32 min (fraction 2 to 
fraction 10) with medium (control), with the D4 receptor agonist RO 10-5824 (100 nM), 
with the D2/3 receptor agonist quinelorane (100 nM) or with both and K+ stimulated 
[3H]glutamate release was determined. Values are mean ± S.E.M. of samples from 3 
different animals performed in 4 replicates. Drug effects were assessed by comparing the 
relative area under the curve for each condition. **p<0.01 and ***p<0.001 with respect to 
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the control and ## p<0.01 with respect to slices treated with RO 10-5824 or quinelorane 
alone (ANOVA followed by Tukey-Kramer multiple comparison post hoc test). In (b), 
slices were treated for 32 min with increasing dopamine concentrations in absence (dark 
circles) or in the presence of the D4 receptor antagonist L-45,870 (10 nM, dark squares), the 
D2 receptor antagonist L 741,626 (10 nM, open circles) or both (open squares) and K+ 
stimulated [3H]glutamate release was determined. Values are mean ± S.E.M. of samples 
from 3 different animals performed in 4 replicates. Drug effects were assessed by comparing 
the relative area under the curve for each condition. The IC50 values were: 25.25 nM (C.I.: 
9.63–66.20 nM) for dopamine alone, 5.75 nM (2.12–15 nM) for dopamine in the presence of 
L-741,626 and 357.27 nM (C.I.: 73.40–1739 nM) for dopamine in the presence of L 
745,870. In (c) slices were treated for 32 min with increasing concentrations of RO 10-5824 
in the absence (black circles) or in the presence (open circles) of quinelorane (10 nM) and 
K+ stimulated [3H]glutamate release was determined. In (d) slices were treated for 32 min 
with increasing concentrations of quinelorane in the absence (black circles) or in the 
presence (open circles) of RO 10-5824 (10 nM) and K+ stimulated [3H]glutamate release 
was determined. In (c) and (d), values are mean ± S.E.M. of samples from 3 different 
animals performed in 4 replicates. The IC50 values were: (c) 15 nM (35.15-6.55 nM) for RO 
10-5824 alone and 0.05 nM (1.21-0.02 nM) for RO 10-5824 in the presence of quinelorane 
(Student’s t test: p<0.01) and (d) 2.55 nM (7.31-0.89 nM) for quinelorane alone and 1.48 
nM (4.5-0.45 nM) for quinelorane in the presence of RO 10-5824 (Student’s t test; NS).
González et al. Page 26
Mol Psychiatry. Author manuscript; available in PMC 2012 December 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
